Discover investment opportunities in Best Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Pharma Stocks using our Smart AI Filter.
10 stocks found for "Best Pharma Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.60 | ±27.2% | 15.6 | 3.47% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.35 | ±28.9% | 6.7 | 5.29% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.37 | ±19.7% | 14.7 | 3.18% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What are the major factors driving the growth potential of Pfizer (PFE)?
A: Pfizer's growth potential is driven by its strong pipeline of new drugs, strategic acquisitions, and vaccines like the COVID-19 vaccine. Patent expirations and competition are important factors to consider for long-term value. Investors often monitor its R&D spending and global market expansion.
Q: How do dividend yields compare between AbbVie (ABBV) and Amgen (AMGN)?
A: AbbVie often offers a higher dividend yield compared to Amgen, influenced by its successful product portfolio, like Humira. Investors consider the sustainability of these dividends by analyzing payout ratios and cash flows.
Q: What sector-specific risks should investors be aware of with Johnson & Johnson (JNJ)?
A: Johnson & Johnson faces risks such as litigation costs from product liability, regulatory compliance, and patent cliffs. Its diversified business model across pharmaceuticals, medical devices, and consumer products mitigates some risks.
Q: Are there any environmental, social, and governance (ESG) considerations for AstraZeneca (AZN)?
A: AstraZeneca is recognized for its commitments to reducing its carbon footprint and ensuring ethical supply chains. ESG-conscious investors may find these initiatives align with their sustainability goals, though continuous evaluation of its ESG performance is advised.
Q: What competitive advantages support Merck's (MRK) market position?
A: Merck's competitive advantages include a robust R&D pipeline, strong oncology segment led by Keytruda, and global distribution networks. These factors help sustain its market position and appeal to growth-focused investors.
Q: How do Novartis (NVS) and Bristol Myers Squibb (BMY) perform in different economic cycles?
A: Novartis and Bristol Myers Squibb typically show resilience during economic downturns, as demand for pharmaceuticals remains relatively stable. However, drug pricing pressures and healthcare regulations can impact performance.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read more